156 related articles for article (PubMed ID: 30652208)
1. The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial.
Huijts CM; Lougheed SM; Bodalal Z; van Herpen CM; Hamberg P; Tascilar M; Haanen JB; Verheul HM; de Gruijl TD; van der Vliet HJ;
Cancer Immunol Immunother; 2019 Mar; 68(3):503-515. PubMed ID: 30652208
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma.
Huijts CM; Werter IM; Lougheed SM; Goedegebuure RS; van Herpen CM; Hamberg P; Tascilar M; Haanen JB; Verheul HM; de Gruijl TD; van der Vliet HJ;
Cancer Immunol Immunother; 2019 Feb; 68(2):319-329. PubMed ID: 30413837
[TBL] [Abstract][Full Text] [Related]
3. Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.
Huijts CM; Santegoets SJ; van den Eertwegh AJ; Pijpers LS; Haanen JB; de Gruijl TD; Verheul HM; van der Vliet HJ
BMC Cancer; 2011 Nov; 11():505. PubMed ID: 22129044
[TBL] [Abstract][Full Text] [Related]
4. Immunological effects of everolimus in patients with metastatic renal cell cancer.
Huijts CM; Santegoets SJ; de Jong TD; Verheul HM; de Gruijl TD; van der Vliet HJ
Int J Immunopathol Pharmacol; 2017 Dec; 30(4):341-352. PubMed ID: 28988508
[TBL] [Abstract][Full Text] [Related]
5. Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus.
Werter IM; Huijts CM; Lougheed SM; Hamberg P; Polee MB; Tascilar M; Los M; Haanen JBAG; Helgason HH; Verheul HM; de Gruijl TD; van der Vliet HJ;
Cancer Immunol Immunother; 2019 May; 68(5):787-798. PubMed ID: 30756132
[TBL] [Abstract][Full Text] [Related]
6. Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.
Kwa M; Li X; Novik Y; Oratz R; Jhaveri K; Wu J; Gu P; Meyers M; Muggia F; Speyer J; Iwano A; Bonakdar M; Kozhaya L; Tavukcuoglu E; Budan B; Raad R; Goldberg JD; Unutmaz D; Adams S
Breast Cancer Res Treat; 2018 Feb; 168(1):57-67. PubMed ID: 29124456
[TBL] [Abstract][Full Text] [Related]
7. Suppression of immune regulatory cells with combined therapy of celecoxib and sunitinib in renal cell carcinoma.
Zhao Q; Guo J; Wang G; Chu Y; Hu X
Oncotarget; 2017 Jan; 8(1):1668-1677. PubMed ID: 27926489
[TBL] [Abstract][Full Text] [Related]
8. Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma.
Orecchioni S; Talarico G; Labanca V; Calleri A; Mancuso P; Bertolini F
Br J Cancer; 2018 May; 118(10):1329-1336. PubMed ID: 29695766
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory effects of everolimus in a long responsive patient with metastatic renal cell carcinoma.
Thiery-Vuillemin A; Laheurte C; Mansi L; Royer B; Pivot X; Borg C; Adotevi O
J Immunother; 2014 Jan; 37(1):51-4. PubMed ID: 24316556
[TBL] [Abstract][Full Text] [Related]
10. Different immunological effects of the molecular targeted agents sunitinib, everolimus and temsirolimus in patients with renal cell carcinoma.
Kobayashi Y; Yamada D; Kawai T; Sato Y; Teshima T; Yamada Y; Nakamura M; Suzuki M; Matsumoto A; Nakagawa T; Hosoi A; Nagaoka K; Karasaki T; Matsushita H; Kume H; Kakimi K
Int J Oncol; 2020 Apr; 56(4):999-1013. PubMed ID: 32319571
[TBL] [Abstract][Full Text] [Related]
11. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.
Shen L; Ciesielski M; Ramakrishnan S; Miles KM; Ellis L; Sotomayor P; Shrikant P; Fenstermaker R; Pili R
PLoS One; 2012; 7(1):e30815. PubMed ID: 22303460
[TBL] [Abstract][Full Text] [Related]
12. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.
Walter S; Weinschenk T; Stenzl A; Zdrojowy R; Pluzanska A; Szczylik C; Staehler M; Brugger W; Dietrich PY; Mendrzyk R; Hilf N; Schoor O; Fritsche J; Mahr A; Maurer D; Vass V; Trautwein C; Lewandrowski P; Flohr C; Pohla H; Stanczak JJ; Bronte V; Mandruzzato S; Biedermann T; Pawelec G; Derhovanessian E; Yamagishi H; Miki T; Hongo F; Takaha N; Hirakawa K; Tanaka H; Stevanovic S; Frisch J; Mayer-Mokler A; Kirner A; Rammensee HG; Reinhardt C; Singh-Jasuja H
Nat Med; 2012 Aug; 18(8):1254-61. PubMed ID: 22842478
[TBL] [Abstract][Full Text] [Related]
13. Oscillatory mTOR inhibition and Treg increase in kidney transplantation.
Sabbatini M; Ruggiero G; Palatucci AT; Rubino V; Federico S; Giovazzino A; Apicella L; Santopaolo M; Matarese G; Galgani M; Terrazzano G
Clin Exp Immunol; 2015 Nov; 182(2):230-40. PubMed ID: 26077103
[TBL] [Abstract][Full Text] [Related]
14. Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity.
Beziaud L; Mansi L; Ravel P; Marie-Joseph EL; Laheurte C; Rangan L; Bonnefoy F; Pallandre JR; Boullerot L; Gamonet C; Vrecko S; Queiroz L; Maurina T; Mouillet G; Hon TN; Curtit E; Royer B; Gaugler B; Bayry J; Tartour E; Thiery-Vuillemin A; Pivot X; Borg C; Godet Y; Adotévi O
Cancer Res; 2016 Jul; 76(14):4100-12. PubMed ID: 27197194
[TBL] [Abstract][Full Text] [Related]
15. Immune modulating effects of low doses of cyclophosphamide and keyhole limpet hemocyanin on peripheral blood immune parameters in patients with metastatic renal cell carcinoma.
Kleinknecht S; Bichler KH; Strohmaier WL
Urol Int; 1992; 48(1):1-8. PubMed ID: 1598724
[TBL] [Abstract][Full Text] [Related]
16. Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma.
Jensen HK; Donskov F; Nordsmark M; Marcussen N; von der Maase H
Clin Cancer Res; 2009 Feb; 15(3):1052-8. PubMed ID: 19188179
[TBL] [Abstract][Full Text] [Related]
17. IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma.
Frederiksen KS; Lundsgaard D; Freeman JA; Hughes SD; Holm TL; Skrumsager BK; Petri A; Hansen LT; McArthur GA; Davis ID; Skak K
Cancer Immunol Immunother; 2008 Oct; 57(10):1439-49. PubMed ID: 18286285
[TBL] [Abstract][Full Text] [Related]
18. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.
Wallin JJ; Bendell JC; Funke R; Sznol M; Korski K; Jones S; Hernandez G; Mier J; He X; Hodi FS; Denker M; Leveque V; Cañamero M; Babitski G; Koeppen H; Ziai J; Sharma N; Gaire F; Chen DS; Waterkamp D; Hegde PS; McDermott DF
Nat Commun; 2016 Aug; 7():12624. PubMed ID: 27571927
[TBL] [Abstract][Full Text] [Related]
19. Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion.
Teng MW; Swann JB; von Scheidt B; Sharkey J; Zerafa N; McLaughlin N; Yamaguchi T; Sakaguchi S; Darcy PK; Smyth MJ
Cancer Res; 2010 Apr; 70(7):2665-74. PubMed ID: 20332236
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
Motzer RJ; Escudier B; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Figlin RA; Hollaender N; Urbanowitz G; Berg WJ; Kay A; Lebwohl D; Ravaud A;
Lancet; 2008 Aug; 372(9637):449-56. PubMed ID: 18653228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
